Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CD74 | P04233 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27093011 | 0.87 | HDAC6 (0.53) | HDAC6ALDH1A1LMNAMEN1NPC1 | |
| SCHEMBL25348959 | 0.80 | HDAC6 (0.58) | HDAC6SNCAMEN1NPC1RAB9A | |
| SCHEMBL22558008 | 0.78 | HDAC6 (0.62) | HDAC6MEN1NPC1RAB9AKMT2A | |
| SCHEMBL24215835 | 0.78 | HDAC6 (0.62) | HDAC6MEN1NPC1RAB9AKMT2A | |
| SCHEMBL29022619 | 0.78 | HDAC6 (0.55) | HDAC6 | |
| SCHEMBL25213319 | 0.78 | HDAC6 (0.56) | HDAC6ALDH1A1LMNAMEN1NPC1 | |
| SCHEMBL25992735 | 0.78 | HDAC6 (0.57) | HDAC6MEN1NPC1RAB9AKMT2A | |
| SCHEMBL554725 | 0.77 | ALDH1A1 (0.64) | ALDH1A1LMNACD74MIFMEN1 | |
| SCHEMBL30425502 | 0.77 | UCHL5 (0.56) | HDAC6SNCANPC1RAB9A | |
| SCHEMBL24599272 | 0.77 | HDAC6 (0.52) | HDAC6MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202823-B2 | 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors | QUIMATRYX, S.L. (ES) | 2025-01-21 | — | — | US | disclosed |
| US-20220213084-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | FUNDACIÓN KERTOR (ES) | 2022-07-07 | — | — | US | disclosed |
| US-20220213084-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | FUNDACIÓN KERTOR (ES) | 2022-07-07 | — | — | US | disclosed |
| CN-114269739-A | 1,3,4- Oxadiazole derivatives as histone deacetylase inhibitors | 奎马特里克斯公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3956324-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | QUIMATRYX, S.L. (ES) | 2022-02-23 | — | — | EP | disclosed |
| WO-2020212479-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | QUIMATRYX, S.L. (ES) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213084-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885ALDH1A1 351/4885LMNA 2947/4885 |
| US-12202823-B2 | 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885ALDH1A1 351/4885LMNA 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.